

## Iconovo and Lonza to collaborate on the formulation development of an intranasal biologic

**Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced that Iconovo and Lonza has initiated a collaboration to develop spray-dried formulations of an intranasal biologic for Iconovo's proprietary intranasal device ICOone Nasal®. This project, with a reformulated substance for obesity, is the first in Iconovo's strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.**

According to the agreement, Lonza will develop spray-dried formulations for administration in the ICOone Nasal® device at its Bend site (Oregon, US), which specializes in addressing bioavailability challenges and modulating pharmacokinetics to meet target product profiles. The collaboration aims to identify the ideal product properties concerning particle size, stability, and device compatibility while preserving biological activity.

The Iconovo inhaler platform, ICOone Nasal®, is a unique and proprietary nasal device that releases the dose when the user inhales. One inhaler and an inhalation through each nostril should administer a standard dose of the biologic compound, challenging the need for today's injected formulation.

"Lonza is a world leader in bioavailability enhancement and renowned for its spray-drying capabilities of biologics. Combined with Iconovo's unique nasal inhaler, we expect the result to be an unprecedented patient-friendly product, and we hope that this cooperation will lead to a fruitful, long-term collaboration that goes beyond this specific project," **says Johan Wäborg, CEO of Iconovo.**

"Our team at Lonza's respiratory center of excellence in Bend is pleased to work with Iconovo on its innovative applications, combining Lonza's particle engineering expertise with Iconovo's state-of-the-art devices. Delivering non-invasive and accessible therapies to patients in need is a focus area for both companies," **says Kim Shepard, Director of Advanced Drug Delivery, Lonza.**

"This collaboration, leveraging Iconovo's innovative intranasal delivery technology alongside our expertise in spray-dried formulations, underscores our commitment to advancing patient care by developing innovative products. We believe that combining our strengths can lead to the development of patient-friendly products and a long-lasting, successful collaboration," **says Jan Vertommen, Vice President, Head of Commercial Development, Lonza Small Molecules.**

### Contacts

---

**Johan Wäborg, CEO**

+46 707 78 51 71

[johan.waborg@iconovo.se](mailto:johan.waborg@iconovo.se)

## About Iconovo

---

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort®. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).

## Attachments

---

[Iconovo and Lonza to collaborate on the formulation development of an intranasal biologic](#)